WOMEN'S HEALTH: U.S. MARKETS FOR REPRODUCTIVE MANAGEMENT PRODUCTS

132 Pages | 31 Exhibits | 2013 Analysis | Forecasts Through 2017 Product Family: Market Reports




OVERVIEW:
The U.S. market for reproductive management products is large and robust, estimated at more than $3.7 billion in 2013. This market, which includes a broad range of contraceptive drugs, contraceptive devices/implants, and fertility drugs, is expected to expand at a healthy compound annual growth rate of more than 7%, increasing by more than $1.5 billion over a span of 5 years.

Despite a sluggish economy, intense competition, pricing pressures, litigation, and the significant impact of generic contraceptives, growth in this market is expected to accelerate at a better than average pace throughout the forecast period, as the contraceptives segment, in particular, benefits from highly positive insurance reimbursement (as a result of the 2010 Affordable Care Act) and increasing consumer affordability. The contraceptives market is also expected to flourish due to the introduction of several safer, more tolerable, lower-dosage, yet highly effective contraceptive drugs, and strong advertising/marketing efforts by major pharmaceutical firms. Additionally, the market is benefiting from increased consumer preference and usage of novel contraceptive devices and implants, which provide a convenient, long-term alternative for preventing pregnancy, especially in women who cannot tolerate, or fail to adhere to required dosing schedules of oral drug therapies.

The U.S. market for reproductive management products will also benefit from continued strong demand for easier-to-use, highly effective fertility drugs, as well as the introduction of new technologies, which are expected to enhance assisted reproductive technology and further improve pregnancy rates and decrease potential side effects.

Overall, the U.S. market for reproductive management products will continue to benefit from the stability and growth of the aging female population in the U.S., which continues to postpone or refrain from childbearing and demand access to highly effective contraceptives and fertility drugs.

This dynamic report from Medtech Insight includes analyses of products, markets, competitors, emerging technology and opportunities. Covered products include oral, transdermal, injectable and emergency contraceptives; contraceptive devices, including intrauterine devices (IUDs), vaginal rings, and subdermal contraceptive implants; and leading fertility drug therapies and devices, among other products.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Contraceptive Drugs and Devices 
ii. Fertility Treatment 
iii. Combined Market Forecast 
iv. Methodology 

Exhibit ES-1: Reproductive Management Products Market, Combined Market Forecast, 2012-2017 
Exhibit ES-2: Reproductive Management Products, Market Forecast, by Product Segment, 2012-2017 
Exhibit ES-3: 2012, Reproductive Management Products Market, Share of Sales, by Product Segment 
Exhibit ES-4: 2017, Reproductive Management Products Market, Share of Sales, by Product Segment 

1. CONTRACEPTIVE DRUGS AND DEVICES

1.1 Contraceptive Drugs 
	1.1.1 Actavis 
	1.1.2 Bayer 
	1.1.3 Janssen Pharmaceuticals/Johnson & Johnson 
	1.1.4 Merck & Company 
	1.1.5 Pfizer 
	1.1.6 Teva Pharmaceuticals/Teva Pharmaceutical Industries 
	1.1.7 Market Forecast 
	1.1.8 Competitive Analysis 
1.2 Contraceptive Devices 
	1.2.1 Actavis 
	1.2.2 Bayer 
	1.2.3 The Female Health Company 
	1.2.4 FemCap 
	1.2.5 Mayer Laboratories 
	1.2.6 Merck & Company 
	1.2.7 Teva Pharmaceuticals/Teva Pharmaceutical Industries 
	1.2.8 Market Forecast 
	1.2.9 Competitive Analysis 
1.3 Nonsurgical Sterilization 
	1.3.1 Bayer 
	1.3.2 Hologic 

Exhibit 1-1: 2013, Selected Contraceptive Drugs 
Exhibit 1-2: 2013, Selected Contraceptive Drugs Under Development 
Exhibit 1-3: The Average Reduction in Menstrual Bleeding Using Natazia Over a 90-day Assessment Phase in 2 Studies 
Exhibit 1-4: Contraceptive Drugs, Market Forecast, 2012-2017 
Exhibit 1-5: 2012, Contraceptive Drugs Market, Share by Supplier 
Exhibit 1-6: 2013, Selected Leading Contraceptive Devices 
Exhibit 1-7: 2013, Selected Contraceptive Devices Under Development 
Exhibit 1-8: The Mirena Intrauterine Device 
Exhibit 1-9: The FemCap Cervical Cap 
Exhibit 1-10: The NuvaRing Vaginal Contraceptive Ring 
Exhibit 1-11: Efficacy of the NuvaRing Compared to Other Contraceptive Methods 
Exhibit 1-12: The Implanon Subdermal Contraceptive Implant 
Exhibit 1-13: Efficacy of Implanon Compared to Other Contraceptive Methods 
Exhibit 1-14: The ParaGard Intrauterine Device 
Exhibit 1-15: Contraceptive Devices, Market Forecast, 2012-2017 
Exhibit 1-16: 2012, Contraceptive Devices Market, Share by Supplier 
Exhibit 1-17: The Essure Three-Step Sterilization Procedure 

2. FERTILITY DRUGS AND DEVICES

2.1 Selected Fertility Drug Treatments 
	2.1.1 Actavis 
	2.1.2 EMD Serono/Merck KGaA 
	2.1.3 Ferring Pharmaceuticals 
	2.1.4 Merck & Company 
	2.1.5 OvaScience 
	2.1.6 Teva Pharmaceuticals/Teva Pharmaceutical Industries 
	2.1.7 Market Forecast 
	2.1.8 Competitive Analysis 
2.2 Embryo Transfer Catheters 
	2.2.1 CooperSurgical/The Cooper Companies 
	2.2.2 Irvine Scientific/JX Group 
2.3 Assisted Natural Conception 
	2.3.1 Cambridge Temperature Concepts 

Exhibit 2-1: 2013, Selected Fertility Drug Therapies 
Exhibit 2-2: 2013, Selected Immunoassays and Fertility Treatments  Under Development 
Exhibit 2-3: Efficacy of Crinone in Maintaining Full-Term Pregnancies Following In Vitro Fertilization Embryo Transfer 
Exhibit 2-4: Efficacy of Crinone in Maintaining Full-Term Pregnancies versus No Supplemental Progesterone for Luteal Phase Support 
Exhibit 2-5: The Gonal-f RFF Pen 
Exhibit 2-6: Fertility Drugs, Market Forecast, 2012-2017 
Exhibit 2-7: 2012, Fertility Drugs Market, Share by Supplier 
Exhibit 2-8: The R.G. Edwards Embryo Transfer Catheters 
Exhibit 2-9: The Classic Ultrasoft Embryo Transfer Catheters and Stylets 
Exhibit 2-10: The DuoFertility Assisted Natural Conception System 

3. COMPANY PROFILES

3.1 Actavis, Inc. 
3.2 Bayer AG 
3.3 Ferring Pharmaceuticals A/S 
3.4 Johnson & Johnson 
3.5 Merck & Company, Inc. 
3.6 Merck KGaA 
3.7 Teva Pharmaceuticals/Teva Pharmaceutical Industries LTD 

APPENDIX:  COMPANY LISTING



COMPANIES COVERED:

  1. Actavis, Inc.
  2. Bayer AG
  3. Cambridge Temperature Concepts LTD
  4. CooperSurgical, Inc./The Cooper Companies, Inc.
  5. EMD Serono, Inc./Merck KGaA
  6. FemCap, Inc.
  7. Ferring Pharmaceuticals, Inc.
  8. Hologic, Inc.
  9. Irvine Scientific/JX Holdings, Inc.
  10. Janssen Pharmaceuticals, Inc./Johnson & Johnson
  11. Johnson & Johnson
  12. Mayer Laboratories, Inc.
  13. Merck & Company, Inc.
  14. Merck KGaA
  15. OvaScience, Inc.
  16. Pfizer, Inc.
  17. Teva Pharmaceuticals/Teva Pharmaceutical Industries LTD
  18. The Female Health Company
Contact Us

Need help finding medtech research? Let us help you!